BioSpace News Archive

bioAffinity Technologies, Inc. announced that the Centers for Medicare and Medicaid Services has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.

Processa Pharmaceuticals, Inc. announces that Dr. David Young, President of Research and Development, will present virtually at the MedInvest Oncology Investor Conference.

Inipharm today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13.

Femasys Inc. today announced the appointment of James Liu, M.D., as Chief Medical Officer.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.

Procyrion, Inc. announced the enrollment of the first patients in the company’s IDE pivotal trial.

Gilgamesh Pharmaceuticals announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist.

Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on December 7, 2023 (the “Conference”).

Adela, Inc. is presenting data today demonstrating the feasibility of using its platform for cfDNA cancer signal quantification and prognostic prediction in early stage non-small cell lung cancer (NSCLC), during the Plenary Abstract Session at the 2023 Multidisciplinary Thoracic Cancers Symposium in New Orleans.